CA
NZ
UK
AU
IND
US
For the first half of fiscal 2026, ended April 30, revenue rose 38.3% to USD 137.5 million, and cash was USD 17.3 million, according to the July 2026 results. A ten-year extension of a Singapore tax exemption through 2035 was announced on July 27. …
GAAP net loss was USD 39.9 million, or USD 0.18 per share, while the non-GAAP loss was USD 0.05 per share, with non-GAAP net loss of USD 10.3 million. The non-GAAP operating loss narrowed to USD 7.2 million from USD 11.3 million. Management highlighted …
Remaining performance obligations, the revenue already contracted but not yet recognized, rose 60% to USD 812.4 million. Net dollar retention on a trailing four-quarter basis was 124%, up from 118% a year earlier, meaning existing customers expanded spending over the past year. A year …
Vivakor operates inCrude Oilgathering, storage and transportation, along with contaminated soil remediation. The second-quarter 2026 report showed revenue of USD 32.1 million, up from USD 29.1 million, and a net loss of USD 2.8 million against USD 12.5 million a year earlier. Six-month revenue …
The story behind the stock is its pending purchase of Realbotix, a maker of AI-powered humanoid robots. Onconetix signed a definitive share exchange agreement in mid-February 2026 to acquire 100% of Realbotix in an all-stock deal. Realbotix holders are expected to own a large …
On November 3, 2026 the company filed a notice that its annual report on Form 20-F for the fiscal year ended June 30, 2026 could not be filed on time. It expects to file within 15 calendar days after the original due date. The …
HeadlineNet Incomeof USD 27.4 million, or USD 0.09 per diluted share, is not an operating profit. It was driven mainly by a USD 78.2 million non-cash gain from the change inFair Valueof common stock warrants, while the third quarter of 2025 showed a net …
TheBusinessis still deeply unprofitable. Gross loss was USD 7.555 million on cost of revenues of USD 10.39 million, and the GAAP net loss was USD 59.23 million, or USD 0.68 a share. Adjusted EBITDA loss narrowed to USD 42.182 million from USD 44.471 million …
Obsidian develops engineered tumor-infiltrating lymphocyte cell therapies for solid tumors. Its lead candidate, OBX-115, is in a Phase 2 study in advanced melanoma and a Phase 1 study in non-small cell lung cancer. The merger with Galera Therapeutics closed in early August 2026 alongside …
Policy support played a large part. The company recognized USD 12.7 million of Section 45Z production tax credits in cost of sales, plus USD 9.2 million withinEquitymethod income. It closed a USD 30.7 million sale of federal tax credits, including a USD 26.0 million …
Please wait processing your request...